The importance of extracellular traps (ETs) in innate immunity is well established, but the molecular mechanisms responsible for their formation remain unclear and in scientific dispute. ETs have been defined as extracellular DNA scaffolds associated with the granule proteins of eosinophils or neutrophils. They are capable of killing bacteria extracellularly. Based mainly on results with phosphoinositide 3-kinase (PI3K) inhibitors such as 3-methyladenine (3-MA) and wortmannin, which are commonly used to inhibit autophagy, several groups have reported that autophagy is required for neutrophil extracellular trap (NET) formation. We decided to investigate this apparent dependence on autophagy for ET release and generated genetically modified mice that lack, specifically in eosinophils or neutrophils, autophagy-related 5 (Atg5), a gene encoding a protein essential for autophagosome formation. Interestingly, neither eosinophils nor neutrophils from Atg5-deficient mice exhibited abnormalities in ET formation upon physiological activation or exposure to low concentrations of PMA, although we could confirm that human and mouse eosinophils and neutrophils, after pre-treatment with inhibitors of class III PI3K, show a block both in reactive oxygen species (ROS) production and in ET formation. The so-called late autophagy inhibitors bafilomycin A1 and chloroquine, on the other hand, were without effect. These data indicate that ET formation occurs independently of autophagy and that the inhibition of ROS production and ET formation in the presence of 3-MA and wortmannin is probably owing to their additional ability to block the class I PI3Ks, which are involved in signalling cascades initiated by triggers of ET formation.
Introduction
Extracellular DNA traps can be generated by several different leucocytes, including neutrophils, eosinophils, basophils and monocytes, as well as mast cells; 1 neutrophil extracellular traps (NETs) have been most frequently studied. Extracellular DNA traps can bind and kill microorganisms in the extracellular space, 2 and most investigators agree that NETs contribute significantly to innate immunity and are seen in vivo with many infectious, allergic and autoimmune diseases. The molecular mechanisms responsible for their formation remain unclear and in dispute. 3 Several groups have reported a requirement for autophagy in the formation of extracellular traps (ETs). The majority of these reports have used pharmacological approaches to demonstrate that Abbreviations: 3-MA, 3-methyladenine; ATG, autophagy-related; Baf A1, bafilomycin A1; C5a, complement factor 5a; CQ, chloroquine; DHR, dihydrorhodamine; EET, eosinophil extracellular trap; EPX, eosinophil peroxidase; ET, extracellular trap; GM-CSF, granulocyte/macrophage colony-stimulating factor; IL, interleukin; LPS, lipopolysaccharide; NET, neutrophil extracellular trap; PI3K, phosphoinositide 3-kinase; PMA, phorbol 12-myristate 13-acetate; ROS, reactive oxygen species
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inhibition of the phosphatidylinositol 3-kinase (PI3K) type III signalling, which is required for autophagosome formation, prevents NET formation, implying a role for autophagy in NET formation. [4] [5] [6] Moreover, controversial findings have been reported regarding the effect of mammalian target of rapamycin on the kinetics of NET formation; both inhibitory and potentiating effects have been observed. 7, 8 Very recently it has been suggested that ageing-related ATG5 defects might impair NET formation. 9 Autophagy is a cellular mechanism responsible for the turnover of macromolecules and organelles via the lysosomal degradative pathway. Cells usually respond with the induction of autophagy following stress. 10 Using wortmannin as an inhibitor of class III PI3K to block PMAinduced NET formation, Remijsen et al. reported that autophagy has a key role in NET formation. 5 It is important to note that wortmannin can also completely inhibit reactive oxygen species (ROS) production in human neutrophils following zymosan, hydrocarbon, tumour necrosis factor-a, or adhesion receptor stimulation. [11] [12] [13] [14] [15] Furthermore, 3-methyladenine (3-MA), another inhibitor of class III PI3K, has been shown to reduce ROS production in activated neutrophils just as efficiently as diphenylene iodonium, a potent inhibitor of ROS production. 13, 16 As ROS have been shown to be essential for NET formation 2, 17 and to be a trigger for autophagy, 18 we addressed the question whether autophagy has a direct role in ET formation by silencing Atg5 in both eosinophils and neutrophils. Its product, ATG5, is required for autophagy, playing an early role in phagophore development and especially in autophagosome elongation. 10 To this end, we generated mice in which Atg5 can be conditionally deleted in eosinophils (hereafter designated Atg5 eoD mice) or in neutrophils (hereafter designated Atg5 ND mice 19 ). Data obtained in ATG5-knockout granulocytes were compared with data from experiments in which pharmacological inhibitors of autophagy were employed in normal mouse and human eosinophils and neutrophils. We report here that ET formation is an autophagy-independent process in both eosinophils and neutrophils.
Methods

Reagents
Human granulocyte-macrophage colony-stimulating factor (GM-CSF) was purchased from Novartis Pharma GmbH (N€ urnberg, Germany). Mouse GM-CSF and human interleukin-5 (IL-5) were purchased from R&D Systems (Abingdon, UK). Human and mouse complement factor 5a (C5a) were from Hycult Biotech (Uden, the Netherlands). German glass coverslips (#1 thickness, 12 mm diameter) were obtained from Karl Hecht GmbH & Co. KG "Assistent" (Sondheim/Rh€ on, Germany). Black, glass-bottom 96-well plates were from Greiner Bio-One GmbH (Frickenhausen, Germany). Lipopolysaccharide (LPS, 055:B5), dihydrorhodamine-123 (DHR123) and saponin were from Sigma-Aldrich (Buchs, Switzerland ) were generated by crossing IL-5 tg mice with Atg5 flox/flox mice.
Purification of mouse neutrophils and eosinophils
Lyz2
Cre/Cre and Atg5 ND mice were analysed between 8 and 12 weeks of age. In additional experiments, mice were between 9 and 10 months old. Primary bone marrow mouse neutrophils were isolated from control and Atg5 ND mice 19 under animal license BE54/15, by a negative selection technique using an EasySep Mouse Neutrophil Enrichment Kit (Stemcell Technologies, Grenoble, France). Briefly, bone marrow cells were collected by flushing the femur with 5 ml of isolation medium (PBS plus 2% fetal calf serum, no EDTA added) using a 26-gauge needle and filtering through a sterile 70-lM nylon cell strainer. Bone marrow single-cell suspensions were then washed with medium and the cells were counted with a haemocytometer using the T€ urk's staining solution (Merck Millipore). Primary bone marrow neutrophils were then isolated by a negative selection technique using the EasySep Mouse Neutrophil Enrichment Kit (Stemcell Technologies) and the isolation medium described above. Mouse neutrophil purity was > 93% as assessed by staining with the Hematocolor Set (Merck Millipore) followed by light microscopic analysis. 19 Mouse eosinophils were isolated from IL5 tg _Atg5
flox/flox and IL5 tg _Atg5 eoD mice, aged between 8 and 12 weeks. For eosinophil isolation, bone marrow cells were collected by flushing the femurs and tibia with medium (2% fetal calf serum in PBS), using a 26-gauge needle, and filtering through a sterile 70-lM nylon cell strainer. Erythrocytes were lysed for 5 min by adding 3 ml of lysis buffer (155 mM NH 4 Cl, 10 mM KHCO 3 and 0Á1 mM EDTA, pH 7Á3). T cells, B cells, macrophages and neutrophils were depleted with antibodies against CD8a, CD19, CD90.2 and Ly-6G (Miltenyi Biotec, Bergisch Gladbach, Germany), using an EasySep Mouse PE Positive Selection Kit (Stemcell Technologies). Mouse eosinophil purity was > 95% as assessed by staining with the Hematocolor Set (Merck Millipore) followed by light microscopic analysis. 22 
Purification of human neutrophils and eosinophils
Written, informed consent was obtained from all blood donors. The Ethics Committee of the Canton of Bern approved this study. Human blood neutrophils were purified from healthy individuals by Ficoll-Hypaque centrifugation as previously described. 23 Briefly, peripheral blood mononuclear cells were separated by centrifugation on Pancoll Human from PAN TM BioTech (PAN-Biotech GmbH, Aidenbach, Germany). The lower layer, consisting mainly of granulocytes and erythrocytes, was treated with erythrocyte lysis solution (155 mM NH 4 Cl, 10 mM KHCO 3 and 0Á1 mM EDTA, pH 7Á3). The resulting cell populations contained > 95% neutrophils as assessed by staining with the Hematocolor Set followed by light microscopic analysis.
For eosinophil isolation, white blood cells were isolated from the lithium-heparinized blood of healthy donors by Ficoll (Biocoll, Biochrom AG) density gradient centrifugation and magnetic beads as previously described. 22 Blood was diluted with PBS, layered onto Ficoll and the peripheral blood mononuclear cells were separated from granulocytes/erythrocytes by centrifugation at 800 g. Erythrocytes were lysed with lysis solution (155 mM NH 4 Cl, 10 mM KHCO 3 and 0Á1 mM EDTA, pH 7Á3) to obtain granulocytes. Eosinophils were isolated with a kit from Stemcell Technologies. Purity of eosinophils was assessed by DiffQuik staining and light microscopy and was > 97%.
Immunoblotting
Protein expression was analysed by immunoblotting. 1 9 10 6 to 5 9 10 6 cells were washed with PBS and lysed in modified RIPA buffer (50 mM Tris-HCl pH 8Á0, 150 mM NaCl, 1% Triton-X-100, 0Á5% sodium deoxycholate, 0Á1% SDS, 2 mM EDTA supplemented with 0Á5 mg/ml pepstatin A and complete protease inhibitor cocktail). Protein concentrations were determined by BCA protein assay (ThermoFisher Scientific) and samples were denatured in reducing Laemmli buffer before separation by SDS-PAGE. Proteins were blotted on a PVDF transfer membrane (Merck Millipore, Billerica, MA) and subsequently probed with the following primary antibodies: mouse anti-ATG5 monoclonal antibody clone 7C6 (1 : 1000; nanoTools, Teningen, Germany, catalogue number #0262-100), rabbit anti-p62 polyclonal antibody (1 : 1000; Novus Biologicals LLC, Littleton, CO, catalogue number #NBP1-48320), rabbit anti-LC3B polyclonal antibody (1 : 1000; Novus Biologicals LLC, catalogue number #NB600-1384) or mouse anti-GAPDH monoclonal antibody clone 6C5 (1 : 5000; Merck Millipore, catalogue number #MAB374). Secondary antibodies coupled to horseradish peroxidase were from GE Healthcare Life Sciences (distributed by VWR International GmbH, Dietikon, Switzerland) and signals were detected by enhanced chemiluminescence (ECL Western blotting substrate, ThermoFisher Scientific) on photosensitive film (ECL Hyperfilm; GE Healthcare Life Sciences).
Cell activation and confocal laser scanning microscopy
Isolated neutrophils or eosinophils were resuspended in X-VIVO TM 15 medium (2Á5 9 10 6 per ml) and pre-incubated for 30 min in the presence or absence of inhibitors; 3-MA (5 mM), wortmannin (100 nM), chloroquine (CQ) (10 lM), bafilomycin A1 (Baf A1) (250 nM) or rapamycin (1 lM). Cells were primed with 25 ng/ml GM-CSF and IL-5, respectfully, for 20 min on untreated glass coverslips, which had previously been washed with acetone, ethanol, ddH 2 O, and baked at a high temperature (200°) oven for 1 hr. Cells were subsequently stimulated with 10 À8 M C5a or 100 ng/ml LPS. Unprimed neutrophils were also incubated with 25 nM PMA for 15 min. Cells were then fixed with 4% paraformaldehyde for 5 min, subsequently washed three times in PBS (pH 7Á4), stained with 1 lg/ml Hoechst 33342 and mounted in ProLong Gold mounting medium. For extracellular DNA detection, staining with cell-permeable fluorescent dyes, such as MitoSOX Red (5 lM), was performed with live cells before fixation according to the corresponding manufacturers' instructions. Neutrophil elastase or EPX co-localization with extracellular DNA was analysed by indirect immunofluorescence as previously described. 23, 24 Briefly, cells were fixed with 4% paraformaldehyde and permeabilized with 0Á05% saponin. Monoclonal mouse antibody to human neutrophil elastase (1 : 1000, clone NP57; Dako, Baar, Switzerland, catalogue number #M0752) or mouse antihuman EPX (1 : 100, clone MM25-82Á2; obtained from Lee Laboratories, Mayo Clinic, Scottsdale, AZ) served as primary antibodies. Alexa Fluor â 488-conjugated secondary antibody was obtained from ThermoFisher and was used at 1 : 400. In these experiments, cells were stained with 10 lg/ml propidium iodide for extracellular DNA detection. Slides were examined and images were acquired by LSM 700 (Carl Zeiss Micro Imaging, Jena, Germany) using a 639/1Á40 Oil DIC objective and followed by analysis with IMARIS software (Bitplane AG, Zurich, Switzerland) as previously reported.
23
Quantification of released dsDNA in culture supernatants
Released dsDNA was quantified as previously described. 23 Briefly, 2 9 10 6 isolated neutrophils or eosinophils in 500 ll of medium (X-VIVO TM 15 for neutrophils, and Medium 199 for eosinophils) were stimulated as described above. At the end of the incubation time, a low concentration of DNase I (2Á5 U/ml; Worthington) was added for an additional 10 min, and proteinase K (0Á2 mg/ml; Roche) was added at the same time to eosinophils only. Reactions were stopped by addition of 2Á5 mM EDTA, pH 8Á0. Cells were centrifuged at 500 g for 5 min. Then, 100 ll supernatant was transferred to black, glass-bottom 96-well plates (Greiner Bio-One GmbH) and the fluorescence activity of PicoGreen dye bound to dsDNA was excited at 502 nm and the fluorescence emission intensity was measured at 523 nm using a spectrofluorimeter (SpectraMax M2; Molecular Devices, Biberach an der Riß, Germany), according to the instructions described in the Quant-iT TM PicoGreen â Assay Kit.
Reactive oxygen species measurements
Measurements of ROS were performed in stimulated mouse and human neutrophils by fluorescent detection of ROS activity using flow cytometry as previously described. 23 Briefly, 2 9 10 6 /ml neutrophils or eosinophils were resuspended in medium, and 100 ll of cell suspension was pre-incubated in the presence and absence of different inhibitors for 30 min, before priming with 25 ng/ml GM-CSF for 20 min. Cells were then stimulated with 10 À8 M C5a or 100 ng/ml LPS. As a control, we also stimulated neutrophils with 25 nM PMA for 15 min without GM-CSF priming. DHR123 was added to the cells at the final concentration of 1 lM. The reaction was stopped by adding 200 ll of ice-cold PBS, the ROS activity of the samples was measured immediately using flow cytometry (BD FACSCalibur) and quantified using FLOWJO software (Treestar, Ashland, OR).
Statistical analysis
Mean values (AE SEM) are provided. To compare groups, one-way analysis of variance was applied. P-values < 0Á05 were considered statistically significant.
Results
Atg5-knockout mouse eosinophils are able to release extracellular DNA
To investigate whether Atg5-knockout mouse eosinophils are capable of forming ETs, eosinophils were isolated from IL5 tg _Atg5 eoD and control IL5 tg _Atg5 flox/flox mice, primed for 20 min with GM-CSF and subsequently activated with C5a or LPS, or alternatively, with PMA in the absence of priming, all known triggers of eosinophil ET (EET) formation.
24 Atg5-knockout eosinophils were able to form EETs just as well as eosinophils from control
IL5
tg _Atg5 flox/flox mice (Fig. 1a) . Eosinophils of IL5 tg _At-g5 eoD mice displayed a complete ATG5 knockout at the protein level and exhibited strongly reduced autophagic activity as assessed by p62 accumulation and reduced LC3-II expression (Fig. 1b) .
To quantify the extracellular DNA scaffolds of EETs formed by activated mouse eosinophils, we collected culture supernatants and measured the amount of released dsDNA using PicoGreen fluorescent dye. 23 As expected, there were large statistically significant differences in dsDNA release between unstimulated and activated eosinophils whether derived from control or from IL5 tg _At-g5 eoD mice (Fig. 1c) . However, we observed no differences in the dsDNA release between activated Atg5-knockout and control mouse eosinophils (Fig. 1c) . Pharmacological inhibitors of autophagy, namely CQ and Baf A1, exhibited no effect on EET formation, whereas other inhibitors, such as 3-MA and wortmannin, blocking both class I and class III PI3Ks, prevented EET formation and significantly reduced the amount of dsDNA release. Rapamycin, known to stimulate autophagy, had no effect on EET formation in either control or Atg5-knockout mouse eosinophils (Fig. 1a and 1c) . In control experiments, we observed an increased autophagic flux following exposure to rapamycin and a reduced autophagic flux as a consequence of 3-MA or wortmannin (d) Total reactive oxygen species activity was assessed by DHR123 fluorescence and flow cytometric analysis. All data are presented as means AE SEM of at least three independent experiments. **P < 0Á01; ***P < 0Á001.
treatment. Moreover, CQ and Baf A1 treatment resulted in an accumulation of LC3-II (data not shown). Atg5-knockout and control eosinophils were able to generate the same amounts of ROS (Fig. 1d) , which is known to be required for EET formation. 24 Taken together, these data suggest that ROS production and DNA release by mouse eosinophils are independent of ATG5 expression and autophagy, but, as expected, do require class I PI3K activity.
Atg5-knockout mouse neutrophils are able to release extracellular DNA To investigate whether the formation of NETs is also independent of ATG5, mouse neutrophils were isolated from Atg5 ND and control Lyz2 Cre/Cre mice and primed for 20 min with GM-CSF and subsequently activated with C5a or LPS, or alternatively, with PMA in the absence of priming, all known triggers of NET formation. 17 Atg5-knockout neutrophils were able to form NETs just as well as neutrophils isolated from control Lyz2 flox/flox mice (Fig. 2a) . Neutrophils of Atg5 ND mice exhibited no detectable ATG5 expression as well as strongly reduced autophagic activity as assessed by p62 accumulation and LC3-II expression (Fig. 2b) . 19 As in the eosinophil system, we also quantified the dsDNA release between Atg5-knockout and control mouse neutrophils. There were large statistically significant differences in dsDNA release between unstimulated and activated neutrophils whether derived from control or from Atg5 ND mice (Fig. 2c) . However, we observed no differences in the dsDNA release between activated Atg5-knockout and control mouse neutrophils (Fig. 2c) . The two pharmacological inhibitors of autophagy CQ and Baf A1 exhibited no effect on NET formation, whereas 3-MA and wortmannin prevented NET formation and significantly reduced the amount of dsDNA release. Furthermore, rapamycin, which stimulates autophagy, had no effect on NET formation ( Fig. 2a and 2c) . Moreover, Atg5-knockout neutrophils were able to generate the same amounts of ROS as controls (Fig. 2d) , known to be required for NET formation. 17 It should be noted that neutrophils from older wild-type mice (9-10 months old) also exhibited no defect in ROS production or NET formation (data not shown). Taken together, silencing the Atg5 gene in mouse eosinophils and neutrophils resulted in autophagy-deficient cells. However, both Atg5-knockouts were able to produce the same amounts of ROS and ETs as the corresponding wild-type granulocytes.
Pharmacological inhibitors of autophagy do not prevent EET formation by human eosinophils
As mouse and human eosinophils differ in some functional responses, we also performed experiments with human eosinophils. To trigger EET formation, we stimulated human eosinophils in the same two ways as mouse eosinophils. We defined the formation of EETs by demonstrating the presence of extracellular DNA fibres associated with granule proteins. 24 3-MA and wortmannin completely abrogated EET formation upon physiological activation with IL-5 and C5a or after exposure to low concentrations of PMA (Fig. 3a) . In contrast, Baf A1, CQ, and rapamycin had no effect as could be confirmed by quantitative assessment of the released DNA (Fig. 3b) . These results indicate that the PI3K inhibitors 3-MA and wortmannin affect EET formation as a consequence of diminished ROS production and not because of blocked autophagy. Indeed, 3-MA and wortmannin abrogated the ability of human eosinophils to produce ROS upon activation, whereas ROS production was not affected by CQ, Baf A1 or rapamycin (Fig. 3c) .
Pharmacological inhibitors of autophagy do not prevent NET formation by human neutrophils
We also performed experiments in the human neutrophil system and stimulated NET formation in the same way as in mouse neutrophils. We defined the formation of NETs by demonstrating the presence of extracellular DNA fibres associated with released elastase. 17 The results were similar to those seen in the eosinophil system: 3-MA and wortmannin completely blocked NET formation upon physiological activation of neutrophils with GM-CSF and C5a or after exposure to low concentrations of PMA. In contrast, CQ, Baf A1 and rapamycin had no effect on NET formation (Fig. 4a) . These data were confirmed by quantification of dsDNA release (Fig. 4b) . Also, as with eosinophils, the ROS data showed that CQ, Baf A1 and rapamycin had no effect, while the PI3K inhibitors 3-MA and wortmannin completely blocked ROS production (Fig. 4c) .
Discussion
Previously published work pointed to the possibility that NET formation required autophagy. 4, 5, 9 It should be noted that these studies used pharmacological inhibitors to block class III PI3K in order to stop the initiation of autophagosome formation. However, it is probable that these inhibitors have additional targets, resulting in an indirect inhibition of NET formation. Moreover, rapamycin, a drug that can induce autophagy, has revealed contrasting results in different studies regarding its influence on NET formation. 7, 8 In a recent study, it was suggested that neutrophils from older mice exhibit decreased expression levels of ATG5 and reduced levels of autophagy. Such neutrophils also had a reduced capacity to generate NETs and the authors implied that autophagy could regulate NET formation. 9 In this study, in order to verify such previous findings, we silenced the Atg5 gene in both mouse eosinophils and neutrophils. We have described the generation of Atg5 ND mice previously, 19 but this is the first report in which Atg5 was specifically deleted in eosinophils. Clearly, the Atg5 eoD mice will be valuable tools to dissect the role of autophagy in eosinophils in future studies. Silencing of Atg5 was followed by the loss of ATG5 protein and reduced levels of autophagy in both granulocyte types. In contrast to the previously published work, however, our data suggest that lack of ATG5 does not influence the formation of ETs in either mouse eosinophils or neutrophils. Both EET and NET formation depend on the activation of the NADPH oxidase, 17, 24 which requires type I PI3K activity.
14 GM-CSF treatment followed by C5a stimulation activates type I PI3K and NADPH activities. 13, 25, 26 Consequently, pharmacological inhibitors targeting type I PI3K will block ROS production and ET formation in both eosinophils and neutrophils. As wortmannin and 3-MA not only block type III, but also type I PI3K activity, the conclusion that autophagy is required for the formation of ETs is unwarranted. In fact, our study supports the assumption that these agents block EET and NET formation by blocking type I PI3K activity. This view is further supported by the lack of any effect after treatment with pharmacological inhibitors (CQ and Baf A1) and activators (rapamycin) of autophagy.
Taken together, this report indicates that neither mature eosinophils nor neutrophils have a requirement for autophagy for EET and NET formation. The strength of our study is that we have obtained the same data in both mouse and human cells and that we have used both genetic and pharmacological approaches. Future work will be required to determine which granulocyte functions depend on autophagy.
